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Abstract
Background: Celecoxib inhibits PGE2 production in cancerous tissue. We previously reported
that PGE2 levels in nipple aspirate fluid (NAF) and plasma were not decreased in women at
increased breast cancer risk who received celecoxib 200 mg twice daily (bid). The endpoints of the
current study were to determine if a short course of celecoxib 400 mg bid would decrease PGE2
levels in women 1) at increased breast cancer risk, and 2) with established breast cancer.
Methods: NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg
bid, and two weeks after washout from 26 women who were at increased breast cancer risk. From
13 women with newly diagnosed breast cancer, NAF from the incident breast and plasma were
collected before and on average 2 weeks after taking celecoxib. Additionally, in nine of the 13
women with breast cancer, NAF was collected from the contralateral breast.
Results:  No consistent change in NAF or plasma PGE2 levels was noted in high risk
premenopausal women. NAF PGE2 levels decreased after celecoxib administration in
postmenopausal high risk women (p = 0.02), and in both the NAF (p = 0.02) and plasma (p = 0.03)
of women with breast cancer.
Conclusion: Celecoxib 400 mg bid taken on average for 2 weeks significantly decreased NAF, but
not plasma, PGE2 levels in postmenopausal high risk women, and decreased both NAF and plasma
PGE2 levels in women with newly diagnosed breast cancer. PGE2 levels may predict celecoxib
breast cancer prevention and treatment efficacy. Our observations are preliminary, and larger
studies to confirm and extend these findings are warranted.
Background
Women at increased breast cancer risk include those with
a strong family history of breast cancer, those with a his-
tory of ductal carcinoma in situ (DCIS) or invasive breast
cancer (IBC), and those with precancerous changes in
their breasts. Eligibility for enrollment in the first
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National Surgical Adjuvant Breast and Bowel Project
(NSABP) breast cancer prevention trial required that a
participant have a > 1.66% projected 5 year probability of
developing IBC [1]. The only accepted treatment for these
women is tamoxifen, which has side effects of hot flashes,
deep vein thrombosis, and uterine cancer. An effective
alternative treatment is desirable.
Cyclooxygenase (COX)-1 and COX-2 may be present in
breast tumors to catalyze the conversion of arachidonic
acid to prostaglandins, prostacyclins, or thromboxanes.
While COX-1 expression is constitutive, COX-2 is induci-
ble [2] and is upregulated in a variety of tumors, including
breast cancers [3]. Prostaglandin (PG)E2 is produced from
arachidonic acid by either COX-1 or -2. PGE2 has tumor
and cell growth promoting activity [4]. Women with
breast cancer with PGE2 levels above 15 ng/g appear to
have a significantly worse survival rate than those with
levels ≤ 15 ng/g [5]. Malignant breast tumors produce
more PGE2 than benign breast tumors or normal breast
tissue [3]. A retrospective analysis of women with and
without breast cancer seen at a single hospital for a one
year period found that the women without breast cancer
were more likely to have taken celecoxib than women
who had developed breast cancer [6].
Nonsteroidal antiinflammatory drugs (NSAIDs), includ-
ing aspirin, indomethacin and ibuprofen, inhibit both
COX-1 and COX-2. Inhibition of COX-1 leads to a
number of adverse effects, including gastrointestinal
ulcers and renal toxicity [7]. Recent efforts have, therefore,
focused on pharmacologic agents such as celecoxib, a clin-
ically available medication which selectively inhibits
COX-2. Preclinical studies suggest that celecoxib is effec-
tive both in preventing and in treating breast cancer in a
dose dependant manner [8,9].
We are currently able to collect breast nipple aspirate fluid
(NAF) from 95% of nonlactating adult females ages 18 to
80 with the use of a modified breast pump [10]. Using our
NAF collection technique, we performed a preliminary
study to determine if 200 mg bid of the COX-2 inhibitor
celecoxib administered for two weeks to women at
increased breast cancer risk would significantly decrease
PGE2 levels in the breast, as measured both in NAF and in
plasma, providing both organ specific and systemic infor-
mation [11]. We observed that PGE2 is concentrated in
NAF compared to matched plasma, but that celecoxib 200
mg bid administered for two weeks did not significantly
decrease PGE2 concentrations in NAF or plasma.
Subjects with familial adenomatous polyposis (FAP) who
received celecoxib for six months at 400 mg bid, but not
those receiving 100 mg bid, demonstrated a significant
reduction, compared to placebo, in mean polyp number
[12]. Consequently, we sought to determine if a short two
week course of celecoxib at a dose of 400 mg bid would
alter NAF and/or plasma PGE2 levels in women at high
risk for, or with newly diagnosed breast cancer. We
observed that celecoxib 400 mg bid lowered PGE2 levels in
the NAF and plasma of women with breast cancer, and in
the NAF of high risk postmenopausal women.
Methods
Subject recruitment
Women were provided an Institutional Review Board
approved protocol and required to give written informed
consent in order to enroll in the study. Subjects evaluated
had to be ≥ 18 years old and be at increased breast cancer
risk, based on the subject having either a Gail model risk
of developing IBC in a 5 year period of > 1.66%, or previ-
ously treated DCIS or IBC (now finished with treatment
and free of disease).
Pregnant and lactating women were not eligible. Women
could not have been currently on NSAIDs, aspirin, a COX-
2 inhibitor, warfarin, or have taken such a medication
within two weeks of enrollment. Subjects could not have
a significant history of peptic ulcer disease, upper gas-
trointestinal bleeding, asthma, or be allergic to sulfona-
mides or NSAIDs. A complete blood count, serum
electrolytes and liver panel had to be within normal lim-
its. Subjects were recruited from the Breast Evaluation
Clinics at the University of Missouri-Columbia.
Intervention
Celecoxib was taken daily for 14 days by women at
increased risk, and for 10 to 24 (median 14) days by
women with recently diagnosed breast cancer. Compli-
ance was assessed through the count of returned pills. All
subjects were required to have taken at least 80% of the
prescribed medication. While the goal was to have women
at increased risk and women with cancer take celecoxib for
the same time period, variability in the operative date
required some flexibility in the latter group.
Specimen collection
For all women, both those with cancer and those at
increased risk, NAF was analyzed from only one breast. If
one breast contained cancer and the other did not, only
NAF from the breast with cancer was analyzed. For serum
collected from women with cancer, PGE2 values were
assigned to the cancer group. For all subjects, NAF was col-
lected from the same breast for each of the three visits. A
detailed account of the NAF collection technique has been
reported [10,13].
Baseline NAF and blood collection were performed prior
to the ingestion of celecoxib. For women at increased risk,
washout NAF and blood samples were collected 14 daysBMC Cancer 2006, 6:248 http://www.biomedcentral.com/1471-2407/6/248
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after stopping celecoxib. Thus, subjects at increased risk
were asked to provide three NAF and three plasma sam-
ples (baseline, after celecoxib, and after washout),
whereas subjects with recently diagnosed cancer provided
two NAF and two plasma samples. Each subject granted
permission for us to contact them yearly to determine if
they had developed new or recurrent breast cancer.
NAF samples were collected into capillary tubes and
stored at -80°C until analysis. Eight mL of blood were also
collected from the subject in a tube containing heparin,
the blood spun for 10 min at 1600 rpm, and the plasma
fraction decanted and stored at -80°C until analysis. All
women had NAF and plasma collected within 12 hrs of
their last dose of celecoxib. The half life of the medication
is 11.5 hrs.
PGE2 analysis
The biomarker chosen for analysis was PGE2, due to its
established link to cancer growth. NAF and plasma sam-
ples were analyzed by immunoassay for their PGE2 con-
tent. NAF and plasma samples were analyzed as per the
manufacturer's instructions (R&D Systems, Minneapolis,
MN). The kit uses a monoclonal antibody to PGE2 to com-
petitively bind the PGE2 in the standard or sample. Briefly,
samples were diluted in 100 μL assay buffer supplied by
the manufacturer, pipetted into appropriate wells, incu-
bated for 18–24 hrs at 4°C, washed, substrate solution
added, followed by 1 hr incubation, and absorbance
measured at 405 nm.
For NAF and plasma analyses, a standard curve was pre-
pared using serial dilutions of PGE2. A linear regression
equation was created from standards of known PGE2 con-
centration, and PGE2 concentrations of unknown samples
fit to the standard curve regression equation, corrected for
aliquot volume and expressed as nanograms of PGE2/mL
of original sample. The goodness of fit of the standard
curve, R2, for NAF samples was 0.999. The goodness of fit
was similar for the plasma samples.
Statistical analysis
Median values of continuous variables were computed for
the various groups of subjects. Due to the potential non-
normality of the data, ranking procedures were used for
all analyses with continuous variables. The Wilcoxon
Rank Sum Test was used to compare independent groups.
Examples of these comparisons include comparing pre-
and postmenopausal women, comparing the cancer to the
high risk group, etc. The Wilcoxon Signed Ranks Test was
used to make within group comparisons such as compar-
ing pretreatment to posttreatment, pretreatment to wash-
out, etc.
Results
Subjects
Subjects were enrolled from May 2003 to December 2004.
Complete recruitment data were available for all subjects
screened in 2004, during which the majority of the sub-
jects analyzed in the study were recruited. In 2004, 158
women were screened, of which 27 were eligible, enrolled
and were evaluable. Reasons for ineligibility included use
of nonallowed medication, medical history, and blood
screen abnormalities. All eligible subjects were evaluable,
which required successful collection of NAF or plasma
and detection of PGE2 before and after treatment in the
samples.
NAF and plasma samples were collected before, 2 weeks
after taking celecoxib 400 mg bid, and two weeks after
washout from 26 women who were at high risk for devel-
oping breast cancer. NAF was successfully collected from
the same breast at for 95% (113/120) of subject visits.
From 13 women with newly diagnosed cancer, NAF from
the incident breast and plasma were collected before and
on average 2 weeks after taking celecoxib 400 mg bid.
Additionally, in nine of the 13 women with breast cancer,
NAF was collected from the contralateral breast. Thus, we
collected 26 NAF and 26 plasma samples from the 26
women at increased risk of breast cancer, plus 9 NAF sam-
ples from breasts contralateral to a breast with cancer, for
a total of 35 NAF samples from breasts at increased cancer
risk. We collected NAF from 12/13 subjects from the
breast containing cancer, as well as plasma in the 13 sub-
jects with cancer (Table 1). In total, 47 NAF and 39 blood
samples were collected at baseline from 39 subjects.
Fewer than half of subjects were premenopausal in both
the high risk and cancer groups. Median age was lower in
high risk subjects than in subjects with breast cancer. All
but one subject recruited was Caucasian. The median
number of celecoxib pills taken was over 95% by subjects
in both the high risk and cancer groups, and all subjects in
both groups took over 80% of the pills that they were
given.
PGE2 concentration decreases in both NAF and plasma of 
women with breast cancer after celecoxib treatment
We evaluated all NAF samples for PGE2 (Table 2). PGE2
levels were not significantly different when comparing
subjects at increased risk to women with cancer. When
evaluating the effect of celecoxib on PGE2, levels did not
significantly change in high risk women, but decreased
significantly among women with newly diagnosed breast
cancer (p = 0.02). Changes in individual subjects after
treatment are illustrated in Figure 1A.
PGE2 concentrations in plasma were determined in all
samples (Table 3). Similar to findings in NAF, PGE2 levelsBMC Cancer 2006, 6:248 http://www.biomedcentral.com/1471-2407/6/248
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were not significantly different when comparing samples
from subjects at increased risk to women with cancer.
When evaluating the changes in PGE2 before vs. after treat-
ment, levels did not significantly change in high risk
women, but decreased significantly in samples from
women with newly diagnosed breast cancer (p = 0.03).
Changes in individual subjects after treatment are illus-
trated in Figure 2.
Celecoxib decreases PGE2 levels in the NAF and plasma of 
postmenopausal women
We next determined if menopausal status influenced the
effect of celecoxib on PGE2  levels (Tables 4 and 5).
Celecoxib significantly decreased PGE2 levels in the NAF
(p = 0.02) but not the plasma of postmenopausal high
risk women. Changes in individual subjects after treat-
ment and after washout are illustrated in Figure 1B.
Celecoxib did not significantly alter PGE2 levels in pre-
menopausal women.
PGE2 levels are higher in pre- than in postmenopausal high 
risk women
Both after treatment (p = 0.04) and after washout (p =
0.003), NAF PGE2 levels were significantly higher in pre-
than in postmenopausal high risk women (Table 4). PGE2
levels in NAF were not different in women with newly
Table 2: Comparison of Median PGE2 Concentrations in ng/mL in NAF Based on Disease Status1
Before (N) After (N) Washout (N) P value
Before v.
After (N)
After v.
Washout (N)
Before v.
Washout (N)
Population2
High risk 11.43 (26) 13.22 (22) 14.30 (22) 0.84 (22) 0.91 (21) 0.67 (22)
Cancer 10.70 (12) 8.11 (11) NA 0.02 (11)
P value 0.37 0.11
1: N: sample size; NAF: nipple aspirate fluid; NA: not applicable.
2: Although NAF was collected from both breasts of women with cancer, only NAF from the breast with cancer is included in this Table. In the high 
risk group, after taking celecoxib NAF collection was unsuccessful in two subjects, and in one the tube broke. In the cancer group, one subject 
refused NAF collection, and in a second subject the after treatment aspiration was not attempted due to the presence of a needle localization wire.
Table 1: 
Demographics
High Risk Cancer
NAF(plasma) NAF(plasma)
Samples 35(26)1 12(13)2
Age (years)
Median 53(50.5) 59(58)
Range 30–81(30–81) 35–77(35–77)
Premenopausal 14(11) 3(3)
Race
White 34(25) 12(13)
Black 0 0
Asian 0 0
American Indian 1(1) 0
Primary risk factors for enrollment
Family history 17(17) 0
Atypia 6(6) 0
History of breast cancer 3(3) 0
New contralateral breast cancer 9(0) 0
New ipsilateral breast cancer 0 12(13)
Concomitant medications
Vitamins 14(12) 3(3)
Alternative therapies 7(4) 1(2)
1: NAF was collected from both breasts of nine women who had cancer diagnosed on one side. NAF from the incident breast was placed in the 
cancer group and from the contralateral breast in the high risk group. Plasma from these women are included only in the cancer group.
2: We were unable to collect NAF from one cancer subject at baseline.BMC Cancer 2006, 6:248 http://www.biomedcentral.com/1471-2407/6/248
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diagnosed breast cancer. After washout, plasma PGE2 lev-
els were higher (p = 0.04) in pre- than in postmenpausal
women (Table 5). No differences in plasma PGE2 levels
were found, either before or after treatment, in women
with newly diagnosed breast cancer. Moreover, NAF and
plasma PGE2 levels were not correlated in either the can-
cer or high risk groups, whether or not they were subdi-
vided by menopausal status.
PGE2 is concentrated in NAF compared to matched plasma
When both NAF and plasma were available from the same
subject, relative concentrations of PGE2 were compared
before and after treatment with celecoxib. In the high risk
(cancer) groups, median concentrations of PGE2 in NAF
were 27.9 (16.4), 63.7 (13.9), and 48.1 (not applicable)
times higher than in corresponding plasma before
celecoxib, after celecoxib, and after washout. The differ-
ences in the ratios of NAF to serum PGE2 levels before vs.
after treatment, before vs. after washout, and after treat-
ment vs. after washout were significant in neither the high
risk nor the cancer group.
Toxicity
In the high risk group, there were 11 subjects who experi-
enced side effects from celecoxib, four of whom dropped
out. In the other 7 subjects, the side effects resolved spon-
taneously. In the four who dropped out, the side effects
(edema in two, diarrhea in one, and heart palpitations in
one) all resolved shortly after stopping celecoxib. Of the
13 subjects with recently diagnosed cancer who received
celecoxib, one had insomnia(this subject is also included
in the at risk group, since NAF was collected from the non-
involved breast) which resolved spontaneously. There
were no dropouts in the cancer group.
Discussion
We carried out experiments to investigate whether the
COX-2 inhibitor celecoxib at a dose of 400 mg bid could
significantly affect endogenous levels of PGE2 in NAF or
plasma of women at risk for breast cancer or in women
with known cancer. This study builds on our initial study,
which found that celecoxib 200 mg bid did not alter PGE2
levels in NAF or plasma under normal, nonstressed condi-
tions.
In the current study, we observed two important findings.
First, PGE2 levels significantly decreased in the NAF, but
not in the plasma, of postmenopausal women at
increased risk of breast cancer. Second, PGE2 levels signif-
icantly decreased in both the NAF and plasma of
celecoxib-treated women with newly diagnosed breast
cancer.
It is unclear why PGE2 levels significantly decreased in
post- but not premenopausal high risk women. We did
not routinely record whether premenopausal subjects
started celecoxib in the first or second half of their men-
strual cycle. We have this information for 10 women in
the high risk group and one woman for the cancer group.
We did not find a significant difference in PGE2 response
to celecoxib in either the high risk or cancer group based
on when the subject started medication in the first or sec-
ond half of her cycle, although sample size limits the reli-
ability of these findings.
In order to assess if PGE2 was concentrated in NAF, we
determined its relative concentration in NAF vs. plasma in
both high risk women and in women with newly diag-
nosed breast cancer. In both groups, PGE2 was concen-
trated in NAF relative to plasma. The NAF/plasma relative
concentration was numerically, although not signifi-
cantly, lower in women with cancer than in those at
increased risk.
The relative concentration of PGE2 in NAF vs. plasma dif-
fered in the current study compared to our earlier study
[11]. There are a number of possible reasons for this. First,
relative concentrations were lower in the cancer group,
which was not present in the earlier study. Second, we
used different kits in the two studies. The kit used in the
current study was chosen because it has been shown capa-
ble of measuring PGE2 in human bodily fluids by other
Table 3: Comparison of Median PGE2 Concentrations in ng/mL in Plasma Based on Celecoxib Dose and Disease Status1
Before (N) After (N) Washout (N) P value
Before v.
After (N)
After v.
Washout (N)
Before v.
Washout (N)
Population2
High risk 0.29 (26) 0.21 (26) 0.25 (23) 0.72 (26) 0.50 (23) 0.70 (23)
Cancer 0.37 (13) 0.30 (12) NA 0.03 (12)
P value 0.16 0.99
1: N: sample size; NA: not applicable.
2: Reasons why blood was not collected: In the high risk group at washout, three subjects refused. In the cancer group, one subject refused blood 
collection after treatment.BMC Cancer 2006, 6:248 http://www.biomedcentral.com/1471-2407/6/248
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PGE2 values in NAF from A) women with breast cancer, and B) high risk postmenopausal women Figure 1
PGE2 values in NAF from A) women with breast cancer, and B) high risk postmenopausal women. Only subjects with before 
and after treatment values (cancer subjects) or with before, after and washout values (high risk subjects) are shown.
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Table 4: Effect of Menopausal Status on Median PGE2 Concentrations in ng/mL in NAF1
Before (N) After (N) Washout (N) P value
Before v.
After (N)
After v.
Washout (N)
Before v.
Washout (N)
Menopausal Population
High risk
Pre- 15.72 (11) 36.06 (11) 27.64 (11) 0.17 (11) 0.76 (11) 0.04 (11)
Post- 5.88 (15)2 6.81 (11) 5.57 (11) 0.03 (11) 0.77 (10) 0.03 (11)
P value 0.18 0.04 0.003
Cancer
Pre- 15.2 (3) 2.40 (3) NA 0.25 (3)
Post- 10.9 (8) 8.27 (8) NA 0.11 (8)
P value 1.00 0.61
1: Abbreviations: NAF: nipple aspirate fluid; N: sample size; NA: not applicable.
2: Before treatment median PGE2 for the 11 subjects with an after treatment comparison value was 8.33, which was significantly higher than the 
after treatment group.
PGE2 values in plasma from women with breast cancer Figure 2
PGE2 values in plasma from women with breast cancer. Only subjects with before and after treatment values are shown.
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investigators [14]. Third, we used a higher dose of
celecoxib (400 mg bid vs. 200 mg bid) in the current
study.
COX-2 expression has been evaluated in preclinical mod-
els and in clinical breast specimens. In a dimethylbenzan-
thracene (DMBA) rat model of breast cancer, celecoxib
was found to dramatically reduce the incidence, multiplic-
ity, and volume of breast tumors relative to control [15].
While COX-2 expression appears to be a good marker of
breast cancer in tissue, the lack of reliable commercial
immunoassays for bodily fluids at the time that the study
was conducted limited our ability to measure this marker
in NAF and plasma.
Conclusion
PGE2 is measurable and is concentrated in NAF compared
to plasma. Plasma concentrations of PGE2 in women with
a predisposition to breast cancer are within the normally
accepted basal range (less than 1 nanogram/mL).
Celecoxib 400 mg bid significantly decreased PGE2 levels
in women with newly diagnosed breast cancer in both
NAF and plasma, and in the NAF of high risk postmeno-
pausal women, consistent with clinical studies evaluating
its effects on colon and duodenal polyps. We acknowl-
edge that additional studies, with a placebo control, are
required to determine whether monitoring NAF eicosa-
noid concentrations will be of value in describing the
development and progression of breast cancer, or in mon-
itoring the effect of candidate chemopreventive agents
such as celecoxib.
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